Chrissy Metz and Rebel Wilson's GLP-1 Partnerships Were Disclosed by Ro and Noom Themselves

The most useful documents in the past year of celebrity GLP-1 news were not published by a magazine. They were published by the companies selling the drugs. Noom announced Rebel Wilson as its Chief Wellness Ambassador in a press release under its own name on September 18, 2025. Ro's page about Chrissy Metz carries the sentence "Chrissy Metz is a paid partner," printed twice. Neither of those is a leak, an allegation, or a thing anyone was caught at. Both are marketing assets, written by the seller, sitting in public. That is the reason to read them: an announcement of a personal medical decision and the launch of a commercial campaign have, in these cases, been the same event, and the paperwork says so before any reporter does.

Ro's page for Metz, read on August 24, 2026, is headed "Former skeptic. Now on Ro." The disclosure appears twice, both times immediately after the same sentence: "After making significant progress and later pausing treatment, Chrissy joined Ro to continue her GLP-1 weight loss journey. Chrissy Metz is a paid partner." The page is not only a profile. It advertises "63 lbs in 17 months on GLP-1s" as a headline figure and carries a product claim — "Average weight loss in 1 year is 20% (vs ~3% with diet and exercise alone)" — which is Ro's own marketing language, resting on a study this desk has not read and is not adopting. The same site lists Serena Williams and Charles Barkley as Ro Ambassadors. Williams has her own page, read the same day, headed "Serena's healthier on Ro" — and unlike Metz's, it carries no paid-partner line. Her relationship is stated in Ro's other material instead: a company release dated August 21, 2025, headed "Serena Williams joins Ro as GLP-1 Celebrity Ambassador," describing a multi-year campaign across digital, broadcast, and out-of-home advertising and disclosing, in Ro's own words, that "Williams' husband is an investor in Ro and serves on its board."

Noom's September 18, 2025 release, read on noom.com and distributed the same day through GlobeNewswire, is headed "Noom Welcomes Rebel Wilson as Chief Wellness Ambassador to Champion Microhabits and Microdose GLP-1s." It announces a free tier whose named features include "access to microdose GLP-1s," plus a national advertising campaign fronted by Wilson, and defines the product as "low-dose GLP-1 therapies, utilizing 25 percent or less of the typically prescribed maintenance dose" — Noom's description of its own offering, quoted because that is what the ambassador is attached to, not because this magazine has any basis to say whether it works. A second release, dated July 20, 2026, launches a campaign called "Lose for Keeps" across national television, streaming, social, and digital, and puts Wilson in her second year in the role. One thing the Noom releases do not do, and it is worth saying rather than gliding past: neither states compensation terms. They name a corporate title and a campaign. Ro is the one that prints the word "paid."

The check worth running was whether the celebrity roundups left the commercial layer out. They did not. That premise was false, and the honest version of this story is the one that says so. "Serena Williams, Rebel Wilson, Lizzo and the Cost of GLP-1 Honesty," written by Carla Sosenko for Us Weekly and dated October 5, 2025, describes Williams as "a celebrity patient ambassador for telehealth company Ro, which sells GLP-1s," says "Wilson is now Noom's chief wellness ambassador, touting the brand's microdosed GLP-1 product," and names "Charles Barkley, an ambassador for Ro." That article also runs at Yahoo Health under the same headline and byline — one piece at two addresses, which is one source, not two. A separate roundup a week later, carried at AOL, bylined OK! Staff and dated October 12, 2025, carries the same ambassador facts in near-identical construction. The Metz coverage did the same on day one: Parade, under Megan Johnson's byline on August 10, 2026, reported that "she's partnered with telehealth company Ro to serve as a paid spokesperson for their GLP-1," and BroadwayWorld's Rachel Stone noted the same day that "she also announced a new partnership with health care company Ro."

So the gap is not an omission. It is what got built on top of a disclosure nobody hid. The same Us Weekly piece that prints the ambassador titles frames the subject as "the Cost of GLP-1 Honesty" and reports that when those disclosures came, "many took it as a betrayal." A reader can hold the ambassador title and the word honesty in the same hand and still end up arguing about a person rather than a campaign, and that is the argument currently running. Nothing here is a charge against anyone. No subject has denied a commercial relationship, and there is nothing for them to deny: the sellers disclosed the relationships first, in their own names, on their own pages.

Lizzo is the counter-case, and she is why this reads as a pattern rather than a rule. On the June 19, 2025 episode of the Just Trish podcast, reported by E! News the same day, she said she had tried Ozempic and stopped: "Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same thing." Of people who use them, she said: "It's not easy. It's a drug to help somebody with something they're struggling with." No commercial relationship between Lizzo and any weight-loss or telehealth company was found for this piece, across her own statements, the roundups naming her, and the ambassador rosters both companies publish — and a negative finding is a negative finding, not proof that none exists. The roundups group her with the ambassadors anyway.

Two things stay unknown and are staying that way here. Two weight figures are in circulation and this desk adopts neither. Ro's page advertises "63 lbs in 17 months on GLP-1s." A figure of 100 pounds runs through the August 2026 coverage — Page Six carried it on August 11, 2026, under Antoinette Bueno's byline, and reports that Metz gave that figure herself in April 2025, to the Daily Mail, crediting strength training rather than any drug. A Blaze Media commentary segment on August 17, 2026 opened by attaching the same 100 pounds to a GLP-1, and cited nothing for it. What period either number covers, and how the two relate, is not established by any document read here. Nobody has named Metz's medication either: not the outlets reviewed for this piece, not Ro's page. Users have speculated; speculation is not a source. What can be said comes from a primary document with no celebrity in it. The Federal Trade Commission's endorsement rule, at 16 CFR 255.5, requires that where "there exists a connection between the endorser and the seller of the advertised product that might materially affect the weight or credibility of the endorsement, and that connection is not reasonably expected by the audience, such connection must be disclosed clearly and conspicuously." Its Example 3(i) describes the same setup, warning that an audience "might not realize that a celebrity discussing a medical procedure in a television interview has been paid for doing so." That is the rule as written, reported because it describes the shape of the thing — not because anything found here suggests anyone broke it. Every relationship located was disclosed by the company itself.

The reason this lands on a plus-size culture desk rather than a business one is that the same commercial expectation is already reshaping what this readership can buy. This magazine reported that retailers cut extended sizing on a forecast of durable population-level weight loss, in "Retail's GLP-1 Forecast Assumes the Weight Stays Off. The Evidence Still Doesn't Agree." and "Target's Plus-Size Selection Fell 37 Percent in a Year, as Old Navy's Slid Too." National advertising campaigns fronted by some of the most recognizable people in American culture, and a retail forecast that assumes the category shrinks, are two ends of the same commercial expectation. The argument people say they are having is about whether these disclosures were honest. The document underneath it is a media plan.